As the United States’ opioid epidemic rages on, health officials are busy looking for ways to help with the response. Now, right on the heels …

In financial distress last May, AstraZeneca spinout Entasis Therapeutics sold out to holding company Innoviva for $113 million. A year later—to the day—Innoviva’s subsidiary has scored its …

Viatris Chairman Robert Coury has called the shots at Mylan and its successor Viatris for many years, but now he’s getting ready to hang it …

After the recent high-profile loss of exclusivity for AbbVie’s megablockbuster immunology drug Humira, industry watchers’ eyes moved to Johnson & Johnson’s Stelara as one of …

An industry-first FDA approval for a nonalcoholic steatohepatitis (NASH) therapy may still be a ways off. After reviewing Intercept Pharmaceuticals’ latest application for obeticholic acid …

News of the Federal Trade Commission (FTC) lawsuit challenging Amgen’s $28 billion buyout of Horizon prompted an immediate question: Will the U.S. antitrust enforcer also attempt to …

After a high-profile rejection for Innovent Biologics’ Tyvyt, another China-made PD-1 inhibitor is starting a bid to win an FDA approval. Elevar Therapeutics has filed …

AbbVie’s aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within …

DeepIntent and Roku want to challenge the idea that watching TV on streaming services is the preserve of the young. With 79% of people aged …

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the appointment of Nick Clare to the ELRIG board. He will chair and lead …